August 11, 2009
A large effectiveness study comparing Schering-Plough's pegylated-interferon Pegintron and ribavirin with Roche's Pegasys and ribavirin shows both hepatitis C treatments worked equally well.
The study by Dr. Mark Sulkowski of Johns Hopkins University involved 3,000 patients with hepatitis C. Its findings are meant to help guide doctors' decisions about which treatments work best.
"There has been a lot of debate about these two regimens," said Dr. Andrew Muir of Duke University, a co-author of the Schering-Plough-funded study. "It's great to have a study of this size that really answers this question."
07.22.2009; Julie Steenhuysen
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Long-Acting HIV Treatment: 5 Myths and Realities|
|Incidence of All Cancers but Lung Cancer Drops After HIV Group Stops Smoking|
|Frame PrEP as Part of a 'Healthy Sex Life' for Better Adherence|
|A New Nuke in the Works -- GS-9131|
|Bictegravir in the Body -- Preliminary Information About Drug Interactions|
|Running a PrEP Clinic in a Community Pharmacy Setting|